Torramade Ribas J, Hernández Lizoáin J L, Benito Fernández C, González Fernández J, Balen Rivera E, Martínez Regueira F, Pardo Sánchez F, Cienfuegos Suárez J A
Departamento de Cirugía General, Facultad de Medicina, Universidad de Navarra.
An Esp Pediatr. 1993 Mar;38(3):251-4.
The need for an access to the venous system, in order to infuse chemotherapeutic treatments or parenteral nutrition, has increased the number of central venous access systems (CVAS) implanted in the past years. Between February 1985 and December 1990, 87 devices were implanted in 76 patients (from 11 months to 15 years of age), with a median function time of 349 days (range: 7 to 1887 days). The overall incidence of complications was 0.10 per 10 days of catheterization, with complication rates for infection and thrombosis of 0.02 and 0.03, respectively. Nineteen systems were removed because of complications and 11 because of completion of the treatment. Of the cases, 97.7% included a follow-up period. The present study confirms the advantages of these devices, with a long working life and a low complication rate, being a good alternative for chronically ill children requiring long-term and/or cyclic intravenous therapy.
为了输注化疗药物或进行肠外营养，需要建立静脉通路，这使得过去几年植入的中心静脉通路系统（CVAS）数量有所增加。1985年2月至1990年12月期间，76例患者（年龄从11个月至15岁）植入了87套装置，中位使用时间为349天（范围：7至1887天）。导管插入术每10天的总体并发症发生率为0.10，感染和血栓形成的并发症发生率分别为0.02和0.03。19套装置因并发症而取出，11套因治疗结束而取出。其中97.7%的病例进行了随访。本研究证实了这些装置的优点，即使用寿命长且并发症发生率低，对于需要长期和/或周期性静脉治疗的慢性病患儿是一种很好的选择。
